Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
Debiopharm
AddedMar 20, 2024
UpdatedJun 28, 2026
Debiopharm

Debiopharm

Strategic digital health investments by Debiopharm Innovation Fund SA.

HQ
Lausanne, canton Vaud, CH
Founded
1979
Overview
Compare
Employees
Website

Debiopharm, founded in 1979 by Dr. Rolland-Yves Mauvernay, is a privately-held Swiss biopharmaceutical company headquartered in Lausanne, Switzerland. The company focuses on the development and clinical testing of innovative drug candidates, with a mission to advance treatments that improve patient outcomes worldwide. Debiopharm offers products such as Triptorelin and Oxaliplatin, targeting various therapeutic areas including oncology and infectious diseases. Additionally, the Debiopharm Innovation Fund SA invests strategically in digital health initiatives.

Notable figures affiliated with Debiopharm include Thierry Mauvernay, President, Bertrand Ducrey, CEO of Debiopharm International SA, and Marc Cikes, Managing Director of the Debiopharm Innovation Fund SA. The company has achieved significant milestones in drug development and commercialization, contributing to the global healthcare landscape. Through its innovative therapies and strategic investments in digital health, Debiopharm has made a substantial impact on improving patient care and advancing medical research.

Debiopharm - Quick Facts

When was Debiopharm founded?

Debiopharm was founded in 1979.

Where is Debiopharm's headquarters located?

Debiopharm's headquarters is located in Lausanne, canton Vaud, CH.

How many employees does Debiopharm have?

Debiopharm has 486 employees as of Feb 10, 2024.

Debiopharm - Classification

Ownership
  • Private
Technology
  • Biotech
Geographic Exposure
  • Global
Revenue
  • Recurring
  • Software
  • Transactional
Customer
  • Enterprise
  • Government
Main Product
  • Drug Development
Tags
  • Biotech
  • Financial
  • Pharma
NAICS
  • 540000Professional, Scientific, and Technical Services
  • 541714Research and Development in Biotechnology (except Nanobiotechnology)
  • 520000Finance and Insurance
  • 523000Securities, Commodity Contracts, and Other Financial Investments and Related Activities
  • 541000Professional, Scientific, and Technical Services
  • 523900Other Financial Investment Activities
  • 541700Scientific Research and Development Services
  • 523990All Other Financial Investment Activities
  • 541710Research and Development in the Physical, Engineering, and Life Sciences
  • 523999Miscellaneous Financial Investment Activities
SIC
  • 6700Holding And Other Investment Offices
  • 8700Engineering, Accounting, Research, Management, And Related Services
  • 6720Investment Offices
  • 8730Research, Development, And Testing Services
  • 6722Management Investment Offices, Open-end
  • 8731Commercial Physical and Biological Research
Show 18 more industry codes
NAICS
  • 320000Manufacturing
  • 325400Pharmaceutical and Medicine Manufacturing
  • 620000Health Care and Social Assistance
  • 325000Chemical Manufacturing
  • 525000Funds, Trusts, and Other Financial Vehicles
  • 623000Nursing and Residential Care Facilities
  • 325410Pharmaceutical and Medicine Manufacturing
  • 523910Miscellaneous Intermediation
  • 325412Pharmaceutical Preparation Manufacturing
SIC
  • 2800Chemicals And Allied Products
  • 6000Depository Institutions
  • 8000Health Services
  • 2830Drugs
  • 6790Miscellaneous Investing
  • 8040Offices And Clinics Of Other Health Practitioners
  • 2834Pharmaceutical Preparations
  • 6799Investors, Not Elsewhere Classified
  • 8049Offices And Clinics Of Health Practitioners, Not Elsewhere Classified